New Two-Pronged cancer drug enters first human tests
NCT ID NCT04603287
Summary
This is an early-stage study testing a new experimental drug called SI-B001 in people with advanced epithelial cancers that have spread and have no standard treatments left. The main goals are to find a safe dose and see how the body processes the drug. The study will enroll about 60 adults whose cancer has continued to grow despite other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC EPITHELIAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510006, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.